Zeria Of Japan Obtains Korean Approval For Ulcer Drug Polaprezinc
This article was originally published in PharmAsia News
Executive Summary
Japanese drug maker Zeria Pharmaceutical May 21 obtained approval from Korea FDA to market Promac (polaprezinc) granule 15 for gastritis and gastric ulcers. Zeria licensed the drug to Korean company SK Chemical and will receive royalties on sales. Korean gastric drug total sales grew by 12.4 percent to ¥12 billion in 2008. Zeria launched Promac granules in 1994 and added an oral disintegrated formulation Promac D75 in 2006. A Phase III study for an additional indication of dysgeusia is ongoing in Japan. (Click here for more - Japanese language